Selux Diagnostics, Inc.
Selux Diagnostics is a Boston-based company dedicated to developing precision diagnostics for infectious diseases. Their mission is to deliver personalized diagnostic information to optimize treatment, combat antibiotic-resistant superbugs, and preserve the lifesaving power of antibiotics. They focus on rapid antimicrobial susceptibility testing (AST) using their proprietary Next Generation Phenotyping (NGP) System to improve patient care and address the global health crisis of antimicrobial resistance.
Industries
Nr. of Employees
medium (51-250)
Selux Diagnostics, Inc.
56 Roland Street, Suite 206, Charlestown, MA 02129, United States
Patents
System, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-12129510-B2
View DetailsSystem, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-11866763-B2
View DetailsAssays for improving automated antimicrobial susceptibility testing accuracy
US-11835523-B2
View Details
System, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-12129510-B2
View DetailsSystem, method and interface for parallel processing of antimicrobial susceptibility tests using different samples
US-11866763-B2
View DetailsAssays for improving automated antimicrobial susceptibility testing accuracy
US-11835523-B2
View DetailsProducts
Next-generation phenotyping (NGP) AST system
Integrated diagnostic platform for rapid phenotypic antimicrobial susceptibility testing that includes automated sample preparation, high-density assay panels, and a high-throughput analyzer to provide same-shift results from isolates and positive blood cultures.
Next-generation phenotyping (NGP) AST system
Integrated diagnostic platform for rapid phenotypic antimicrobial susceptibility testing that includes automated sample preparation, high-density assay panels, and a high-throughput analyzer to provide same-shift results from isolates and positive blood cultures.
Services
Webinars, conference presentations, and educational material focused on rapid AST, breakpoint updates, and antimicrobial stewardship.
Online customer hub, technical help email, and support resources for instrument and assay users.
Guidance and data to help laboratories validate assays and implement current clinical breakpoints.
Webinars, conference presentations, and educational material focused on rapid AST, breakpoint updates, and antimicrobial stewardship.
Online customer hub, technical help email, and support resources for instrument and assay users.
Guidance and data to help laboratories validate assays and implement current clinical breakpoints.
Expertise Areas
- Rapid antimicrobial susceptibility testing
- Direct-from-blood-culture diagnostic workflows
- Assay development and analytical methods for AST
- Clinical and multi-site performance validation
Key Technologies
- Rapid phenotypic AST
- Direct-from-positive-blood-culture testing
- 384-well high-density assay panels
- Viability assays
News & Updates
The FDA has cleared the Selux NGP System for rapid antibiotic susceptibility testing directly from positive blood culture, enhancing the speed and accuracy of diagnostics.
Selux Diagnostics has announced an additional $48 million in funding to support the development and commercialization of their rapid AST platform.
The company received FDA clearance for their Gram-Negative Panel, expanding their diagnostic capabilities.
Selux aims to outsmart bacteria with rapid AST to help prevent the rise of antibiotic resistance and save lives.
This article discusses how rapid AST technologies can significantly improve patient outcomes by providing faster and more accurate susceptibility results.
This article explores the importance of rapid AST in clinical settings, highlighting its benefits in terms of speed, accuracy, and impact on healthcare costs.
The FDA has cleared the Selux NGP System for rapid antibiotic susceptibility testing directly from positive blood culture, enhancing the speed and accuracy of diagnostics.
Selux Diagnostics has announced an additional $48 million in funding to support the development and commercialization of their rapid AST platform.
The company received FDA clearance for their Gram-Negative Panel, expanding their diagnostic capabilities.
Selux aims to outsmart bacteria with rapid AST to help prevent the rise of antibiotic resistance and save lives.
This article discusses how rapid AST technologies can significantly improve patient outcomes by providing faster and more accurate susceptibility results.
This article explores the importance of rapid AST in clinical settings, highlighting its benefits in terms of speed, accuracy, and impact on healthcare costs.